Water-Jel Technologies Recalls Lidocaine Wound Gel Over Failed pH Specifications, Impacting US Supply Chains
Water-Jel Technologies, LLC has initiated a nationwide Class III recall for 31,488 tubes of Lidocaine Wound Gel due to failed pH specifications. This event, originating from their Huntersville, NC facility, necessitates immediate action for procurement and regulatory teams. Businesses must assess supply chain exposure and review quality control protocols for topical analgesics to mitigate commercial risks.
FDA Identifies Critical pH Specification Failure in Water-Jel Lidocaine Wound Gel
Water-Jel Technologies, LLC, based in Huntersville, NC, has initiated a voluntary Class III recall for 31,488 tubes of its Lidocaine Wound Gel, specifically lots A5014, A5018, and A5019. The recall, designated D-0509-2026 and commencing on April 7, 2026, stems from the product's failure to meet established pH specifications. This Lidocaine Wound Gel, containing 0.13% Benzalkonium Chloride and 2% Lidocaine Hydrochloride, is distributed nationwide in the USA by CVS Pharmacy, Inc. For procurement directors and regulatory affairs heads, this pH deviation is a critical quality attribute failure. The pH level of a topical drug product directly impacts its stability, efficacy, and patient safety profile. An incorrect pH can compromise the active pharmaceutical ingredients' (APIs) integrity, potentially reducing the anesthetic effect of Lidocaine Hydrochloride and the antiseptic action of Benzalkonium Chloride. Furthermore, it can lead to skin irritation or altered absorption rates, posing an unquantified but inherent risk to consumers using the product for minor wounds. Businesses sourcing similar topical formulations must immediately scrutinize their suppliers' quality control data for pH compliance and stability testing.
Water-Jel Technologies' Huntersville Facility Under Scrutiny for Quality Control
The recall of Lidocaine Wound Gel places the manufacturing operations of Water-Jel Technologies, LLC at its Huntersville, NC facility (13359 Reese Blvd East, 28078) under direct regulatory and commercial scrutiny. This facility is responsible for producing the 31,488 tubes of the affected product, which are widely distributed across the United States. While specific details on the facility's overall capacity or other products manufactured there are not disclosed in the immediate recall data, its role as the origin point for a nationwide recall of a topical drug product is significant. For supply chain VPs and business development executives, this event signals potential vulnerabilities in the quality management systems at the Huntersville site. Any company currently sourcing active pharmaceutical ingredients (APIs) or finished drug products from Water-Jel Technologies, LLC should initiate a comprehensive risk assessment of their current contracts and supplier qualification documentation. This includes reviewing recent audit reports, CAPA plans, and batch release data to ascertain the robustness of their quality controls, particularly for critical parameters like pH in topical formulations. The incident underscores the need for continuous vigilance over manufacturing site compliance.
Supply Chain Exposure: Nationwide Impact for CVS Pharmacy and Topical Analgesics Market
The nationwide distribution of Water-Jel Technologies' Lidocaine Wound Gel, facilitated by CVS Pharmacy, Inc., highlights significant supply chain exposure. As a major retail pharmacy chain, CVS Pharmacy, Inc. (One CVS Drive, Woonsocket, RI 02895) would have stocked these 31,488 tubes across numerous outlets, reaching a broad consumer base in the USA. This recall necessitates extensive logistical operations for product retrieval, quarantine, and disposal, incurring substantial costs and operational disruptions for the distributor. For procurement directors and supply chain VPs, this event underscores the ripple effect of quality failures at the manufacturer level. Companies that rely on Water-Jel Technologies, LLC for other topical analgesic or antiseptic products, or those that distribute similar OTC medications, must immediately assess their inventory and distribution channels for potential contamination or quality issues. The commercial impact extends beyond the recalled product, potentially affecting consumer confidence in private label brands or other products sourced from the same manufacturer. Proactive communication with distributors and retailers is paramount to manage customer expectations and maintain market integrity.
Strategic Sourcing: Identifying Alternative Suppliers for Topical Lidocaine Formulations
In light of the Water-Jel Technologies recall, procurement teams must proactively identify and qualify alternative suppliers for Lidocaine Hydrochloride and Benzalkonium Chloride-based topical formulations. While the Knowledge Graph does not specify alternative suppliers for Water-Jel, the market for topical analgesics and antiseptics is diverse. Key considerations for sourcing include: * **API Sourcing:** Evaluate manufacturers of Lidocaine Hydrochloride API and Benzalkonium Chloride API with robust quality systems and proven track records of meeting pharmacopoeial specifications, including pH stability. * **Finished Product Manufacturers:** Identify FDA-registered contract manufacturing organizations (CMOs) specializing in topical gels and ointments. Prioritize those with strong analytical capabilities and a history of successful regulatory inspections. * **Qualification Timelines:** Recognize that qualifying new suppliers is a time-intensive process, often requiring comprehensive audits, stability studies, and regulatory filings. Initiating this process immediately is crucial to mitigate future supply risks. * **Geographic Diversity:** Diversifying the supplier base across different regions can reduce the impact of localized regulatory actions or manufacturing disruptions. This strategic approach ensures business continuity and minimizes reliance on a single source, particularly for critical over-the-counter medications.
Broader Regulatory Environment: Heightened Scrutiny on Topical Drug Quality
While the Knowledge Graph does not detail prior regulatory actions specifically against Water-Jel Technologies, LLC, this recall of Lidocaine Wound Gel for failed pH specifications occurs within a period of heightened FDA scrutiny on drug product quality. Recent parallel events underscore a broader industry challenge in maintaining robust quality control systems. For instance, Spectra Medical Devices faced a Class II recall for Lidocaine HCl Injection due to sterility assurance deficiencies on June 10, 2026. This indicates a consistent regulatory focus on the quality and manufacturing integrity of lidocaine-containing products. Other significant recalls, such as Essential Wellness Pharma's Progesterone Injection for sterility issues and Guardian Drug Co. Inc.'s antacids for metallic contamination, further illustrate the FDA's low tolerance for deviations from Current Good Manufacturing Practices (cGMP). For regulatory affairs heads and quality assurance teams, this trend mandates a proactive review of internal quality systems, particularly for critical parameters like pH, sterility, and impurity profiles. The FDA's consistent enforcement actions signal that companies must invest in robust process controls and analytical testing to prevent similar quality failures and avoid more severe enforcement, such as Warning Letters or Import Alerts.
Remediation Pathway and Future Regulatory Implications for Water-Jel Technologies
Water-Jel Technologies, LLC's immediate responsibility following the Class III recall (D-0509-2026) is to ensure effective removal of the affected Lidocaine Wound Gel from the market and to conduct a thorough root cause analysis. This involves identifying precisely why lots A5014, A5018, and A5019 failed pH specifications. Remediation will require implementing robust Corrective and Preventive Actions (CAPA) to address the underlying manufacturing process, raw material quality, or analytical testing deficiencies. The company will need to demonstrate to the FDA that these CAPA measures are effective and sustainable to prevent recurrence. For senior decision-makers, the ongoing status of this recall indicates that the market disruption is not yet resolved. While a Class III recall carries a lower health risk, the FDA will monitor the firm's recall effectiveness checks and the adequacy of its CAPA plan. Future FDA inspections of the Huntersville, NC facility will likely focus on the controls for critical quality attributes, particularly pH, for all topical drug products. Businesses engaged with Water-Jel Technologies, LLC should request detailed CAPA reports and consider independent audits to verify the integrity of their quality systems, safeguarding their own supply chains and brand reputation.